Edgar Filing: Seres Therapeutics, Inc. - Form 4

Seres Therap Form 4 June 21, 201										
FORM	Л								PPROVAL	
Check th	UNITED	STATES		RITIES An ashington			E COMMISSIO	N OMB Number:	3235-0287	
if no long subject to Section 1 Form 4 o Form 5 obligatio may cont	ger 5. 6. 5. 6. 5. 6. 5. Filed put ^{ns} Section 17(STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section							Expires: January 31, 2005 Estimated average burden hours per response 0.5	
See Instruction 1(b).	uction	30(h)	of the I	nvestmen	t Compar	y Act of 1	.940			
(Print or Type I	Responses)									
1. Name and Address of Reporting Person <u>*</u> Ausiello Dennis A			2. Issuer Name and Ticker or Trading Symbol Seres Therapeutics, Inc. [MCRB]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
	(First) (THERAPEUTI IDNEY STREE			of Earliest T Day/Year) 2017	ransaction		X Director Officer (giv below)	109	e) % Owner her (specify	
(Street) CAMBRIDGE, MA 02139			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting				
(City)	(State)	(Zip)				~	Person			
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	-	ed Date, if	3. Transactio Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, 4 Amount	ies (A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	of, or Beneficia 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Reminder: Rep	oort on a separate line	e for each cla	ass of sec	urities bene	Perso inform requir	ns who rest nation cont ed to resp sys a curre	or indirectly. spond to the colle tained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	D
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	S

(Instr. 3)	Price of Derivative Security	(Mo	onth/Day/Year)	(Instr.	8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)					(
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	5
Stock Option (right to buy)	\$ 11.21	06/20/2017		А		15,000		<u>(1)</u>	06/19/2027	Common Stock	15,000	

Reporting Owners

Reporting Owner Name / Address				
	Director	10% Owner	Officer	Other
Ausiello Dennis A C/O SERES THERAPEUTICS, INC. 200 SIDNEY STREET CAMBRIDGE, MA 02139	Х			
Signatures				
/s/ Thomas J. DesRosier, Attorney-in-Fact		06/21/2017		
**Signature of Reporting Person		Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests in full on the earlier of June 20, 2018 or the day immediately prior to the company's 2018 annual meeting of shareholders.

Remarks:

Exhibit List Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(